Uvkan

Uvkan is a pre-clinical stage biotechnology company focused on developing novel small molecule therapeutics for oncology. The company's primary focus is on targeting the CXCR4/SDF-1 signaling pathway, which plays a critical role in tumor growth, metastasis, and the recruitment of immunosuppressive cells to the tumor microenvironment. Uvkan's lead programs aim to overcome the limitations of existing CXCR4 inhibitors by improving oral bioavailability and safety profiles. By disrupting the interaction between CXCR4 and its ligand CXCL12, the company seeks to mobilize cancer cells from protective niches and enhance the efficacy of chemotherapy and immunotherapy.